Drug Trial Radar · NCT02671435
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
383
Actual
Start
Feb 22, 2016
Primary completion
Oct 26, 2021
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).
Conditions
- Advanced Solid Tumors
Interventions
MonalizumabDrug
Participants will receive IV infusion of monalizumab as stated in arm description.
DurvalumabDrug
Participants will receive IV infusion of durvalumab as stated in arm description.
CetuximabDrug
Participants will receive IV infusion of cetuximab as stated in arm description.
mFOLFOX6Drug
Participants will receive IV infusion of mFOLFOX as stated in arm description.
BevacizumabDrug
Participants will receive IV infusion of bevacizumab as stated in arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 through 246.9 weeks (maximum observed duration)
- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
- Change From Baseline in Respiratory Rate (RR)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
- Change From Baseline in Pulse Rate (PR)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
- Change From Baseline in Body Temperature (BT)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
- Change From Baseline in Oxygen Saturation (OS)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
- Number of Participants With Notable Change in QTcF and QTcB From BaselineTime frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
- Number of Participants With at Least 2-Grade Shift From Baseline in Laboratory ParametersTime frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From Day 1 to 28 days after the first dose of study drugs
- Percentage of Participants With Objective Response (OR) in Exploration Cohorts C1A and C1BTime frame: Baseline (Days -28 to -1) through 54.8 months (maximum observed duration)
Locations
49 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Scottsdale, Arizona
Research Site
Duarte, California
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Sacramento, California
Research Site
Santa Monica, California
Research Site
Aurora, Colorado
Research Site
Tampa, Florida
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
New Brunswick, New Jersey
Research Site
New Hyde Park, New York
Research Site
New York, New York
Research Site
The Bronx, New York
Research Site
Providence, Rhode Island
Research Site
Nashville, Tennessee
Research Site
Dallas, Texas
Research Site
San Antonio, Texas
Research Site
Salt Lake City, Utah
Research Site
Blacktown, Australia
Research Site
Clayton, Australia
Research Site
Waratah, Australia
Research Site
Brussels, Belgium
Research Site
Edegem, Belgium
Research Site
Leuven, Belgium
Research Site
Vancouver, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Marseille, France
Research Site
Nantes, France
Research Site
Debrecen, Hungary
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Grafton, New Zealand
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.